Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia

Medicin og biovidenskab

• Incretins 100%
• Non-alcoholic Fatty Liver Disease 82%
• Fasting 61%
• Type 2 Diabetes Mellitus 28%
• Glucose 24%
• Liver Diseases 19%
• Glucose Tolerance Test 15%
• Intravenous Infusions 15%
• Glucagon-Like Peptide 1 9%
• Glucagon 8%
• Research Design 6%
• Age Groups 5%
• Body Mass Index 5%
• Peptides 4%